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What does this study add?
• Ustekinumab had higher drug survival than secukinumab, adalimumab, infliximab and etanercept. Secukinumab appeared to have the lowest drug survival and highest risk of adverse events.
• Results were comparable between originators and biosimilars.
• These findings may affect choice of therapy for candidates for biological therapy, including both bio-na€ ıve and currently well treated patients who are currently, as well as those who have failed on one or more biological agents.
Over the past two decades, the development of biological agents has had a profound impact on management of moderate-to-severe plaque psoriasis and other inflammatory diseases such as psoriatic arthritis (PsA). 1 In clinical trials, drugs that target interleukin (IL)-12/23 and IL-17 have shown remarkable rates of skin clearance, with a much faster onset of action compared with older biologics that inhibit tumour necrosis factor (TNF)-a. 2, 3 However, use of biologics is associated with a much higher cost than traditional treatment options, 4 and these medications may lose their effectiveness after longterm use. 5 Drug survival is defined as the probability that patients will remain on a given drug, whereas discontinuation of therapy can occur for a number of reasons, the most common being lack of efficacy. 6 The following biologics are approved for treatment of moderate-to-severe psoriasis in Denmark: two monoclonal antibodies and one receptor targeting TNF-a, i.e. adalimumab A biosimilar is a biological agent that is similar but not identical to the reference product (henceforth the 'originator'). The introduction of biosimilars has become a way to decrease medical care costs and increase patient treatment options. 7 In May 2015, a national policy was put in place in Denmark stating that patients should be started on, or switched to (in the case of patients who are currently treated and well already on this therapy) the cheapest version of the biologic, that is, the biosimilar version. 8 Previous studies have suggested that drug survival is higher for ustekinumab, and that this drug has a more favourable safety profile than etanercept, adalimumab and infliximab. 6, [9] [10] [11] 
Patient selection criteria
Patients were included if they had a minimum treatment duration of 1 month with either adalimumab, etanercept, infliximab, secukinumab or ustekinumab. We excluded patients who were treated with these drugs as part of a clinical trial.
As previously described, 6 data in DERMBIO are set up as treatment series/sequences of continuous treatment with the same biological drug. If treatment with one drug is discontinued, a new treatment series will commence when treatment with another drug (or the same one as previously used) is started. In accordance with previous analyses, 6 treatment sequences were merged together if the same drug was used in two consecutive series and the discontinuation was less than 1 month for adalimumab and etanercept, less than 2 months for infliximab and secukinumab, and less than 4 months for ustekinumab. In analyses of etanercept and infliximab, series were joined if patients were switched between Enbrel and Benepali, and Remicade and Remsima, respectively. The majority of patients were treated in academic hospital centres (85% of all treatment series), whereas a smaller proportion was seen in private clinics, predominantly in the first years of the study period. From the academic hospital centres, 100% of treatment series are reported, whereas the coverage from the private clinics is estimated to be greater than 80%. 6 To ensure the highest data integrity, and enable comparison with previous reports, 6 we only included data from hospital clinics.
Statistical analysis
We present patient characteristics as frequencies with percentages for categorical variables and means with standard deviations for continuous variables. Survival analyses were performed using Cox regression in which sex, PsA and concomitant methotrexate use were chosen a priori and included as covariates in the adjusted models. 6, 10 We used Kaplan-Meier plots for descriptive (unadjusted) survival curves. For analyses of the Psoriasis Area and Severity Index (PASI) response probabilities, estimates were adjusted for established predictors of therapeutic response, i.e. sex, baseline PASI and body weight. 17 Body weight was chosen over body mass index, as dosage of ustekinumab is based on body weight (≤ 100 kg or > 100 kg), as is infliximab (5 mg kg À1 ).
In analyses of patients who were well treated on an originator who switched to a biosimilar, we compared the 2-year retention rate for Remsima with a cohort of all patients receiving treatment with Remicade on 1 March 2013 (2 years before Remsima was marketed). Similarly, we compared the 6-month retention rate for Benepali with a cohort of all patients receiving Enbrel on 1 September 2015 (6 months before Benepali was marketed). This methodology was chosen to ensure comparability with a recent study by Glintborg et al. 18 of switching in patients with PsA, rheumatoid arthritis and axial spondyloarthritis. For analyses of the 2-year and 6-month retention rates, respectively, we used Cox proportional hazards regression with a robust variance calculation implemented to account for repeated participants. We considered P < 0Á05 as statistically significant in 2-sided tests, and results are reported with 95% confidence intervals (CIs), where applicable. All analyses were performed with SAS statistical software version 9Á4 (SAS Institute Inc., Cary, NC, U.S.A.).
Results
The study population comprised a total of 2161 patients with moderate-to-severe plaque psoriasis receiving biological therapy for at least 1 month, between 1 January 2007 and 31 March 2017. In total, there were 3495 treatment series including 1332 with adalimumab, 579 with etanercept (621 when stratified by brand name; 566 with Enbrel and 55 with Benepali), 333 with infliximab (356 when stratified by brand name; 266 with Remicade and 90 with Remsima), 1055 with ustekinumab and 196 with secukinumab, respectively. Patient characteristics at the time of first treatment series with the respective drugs are shown in Table 1 and Table S1 (see Supporting Information).
Drug survival of adalimumab, etanercept, infliximab, secukinumab and ustekinumab
Overall, ustekinumab was associated with the highest drug survival and lowest risk of drug discontinuation (Figs 1 and 2). Drug survival appeared higher for bio-na€ ıve patients than patients who had previously failed on one or more biological agent. Following failure because of lack of efficacy on one TNF inhibitor, risk of discontinuation (second treatment with a biological agent) was significantly higher with etanercept than infliximab, adalimumab and ustekinumab, respectively, whereas the remaining estimates were nonsignificant (Fig. 2) . Among patients failing on ustekinumab as the first-line therapy, the risk of drug discontinuation was not significantly different between any of the respective drugs. Additional adjustment for number of previous treatments is shown in Figure S1 (see Supporting Information).
As dose escalation may prolong drug survival, we performed a sensitivity analysis where patients were considered to have failed treatment if their dose was increased above the approved European Medicines Agency (EMA) label. In this analysis, drug survival was still highest for ustekinumab, followed by adalimumab ( Fig. S2 ; see Supporting Information). The 'novelty factor' may affect treatment decisions, 19 and thus patients who are currently well treated may theoretically be switched when a new drug enters the market. Examinations showed that 81Á8% and 11Á7% of non-na€ ıve patients who switched to secukinumab did so because of lack of efficacy and adverse events, respectively, on the previous biological agent (47Á4% switched from ustekinumab). Of non-na€ ıve patients, 29Á2% of those who failed on secukinumab were switched back to the immediately preceding therapy.
Drug survival in patients who were well treated on an originator and switched to a biosimilar
In analyses of switching between an originator and a biosimilar, a total of 114, 34, 147 and 44 treatment series were included for Remicade, Remsima, Enbrel and Benepali, respectively. Of patients who were well treated and switched from the originator, patients had been treated with Enbrel and Remicade for a median of 2089 and 1589 days, respectively, when the switch occurred.
There were no significant differences in risk of discontinuation between Remsima compared with Remicade [crude hazard ratio (HR) 1Á64, 95% CI 0Á69-3Á89, P = 0Á264] or Benepali compared with Enbrel (crude HR 0Á46, 95% CI 0Á11-1Á98, P = 0Á297) (Fig. 3) . Adjustment for differences in sex, methotrexate use, and PsA did not significantly alter the results for Remsima compared with Remicade (adjusted HR 1Á45, 95% CI 0Á61-3Á45, P = 0Á403) or Benepali compared with Enbrel (adjusted HR 0Á50, 95% CI 0Á11-2Á02, P = 0Á317).
Onset of action, dosing patterns and efficacy of biologics
Among patients achieving a PASI 75 (≥ 75% improvement from baseline PASI), PASI 90 (≥ 90% improvement) or PASI 100 (100% improvement) response, the time from start of therapy to response was shortest for secukinumab. Betweendrug comparisons of the chance of achieving these responses are shown in Table 2 .
Contrary to clinical trials, patients in daily clinical practice do not undergo washout periods prior to initiation of biological therapy. Absolute PASI reductions may thus be more appropriate for assessment of treatment efficacy than relative reductions (e.g. PASI 75). 20 Consequently, we assessed the absolute PASI reductions, that is, the proportion of patients (with a baseline PASI > 5) who obtained a PASI ≤ 5, ≤ 2, or ≤ 1, respectively, during therapy (Table S2 ; see Supporting Information). Secukinumab had the highest proportion of patients achieving a PASI of ≤ 2 or ≤ 1, respectively (but not ≤ 5), among bio-na€ ıve patients, whereas the highest proportions for non-na€ ıve patients were seen with adalimumab. Using ustekinumab as the reference, adjusted analyses yielded the highest HRs for achievement of these responses with secukinumab in bio-na€ ıve patients, but not in non-na€ ıve patients. Efficacy up to 52 weeks of therapy is shown in Figures S3-S5 (see Supporting Information). Effects on the Dermatology Life Quality Index are shown in Figure S6 (see Supporting Information). Cause-specific discontinuation and availability of PASI data are shown in Figures S7 and S8 (see Supporting Information).
During the first 24 weeks of therapy (including the induction dose), 3Á5%, 39Á0%, 22Á7%, 0Á0% and 20Á0%, of patients were treated with a higher dose of adalimumab, etanercept, infliximab, secukinumab and ustekinumab, respectively, than the EMA-label dose. During maintenance therapy (weeks 25-52), the EMA-label dose was exceeded in 0Á9%, 35Á1%, 56Á7%, 0Á0% and 46Á2% of patients, on adalimumab, etanercept, infliximab, secukinumab and ustekinumab, respectively (Table S3 ; see Supporting Information).
Safety of biologics and biosimilars
For adalimumab, etanercept, infliximab and ustekinumab, adverse events were comparable with previously published observational studies for biological registers (Table 3) . 21 The highest rate of infections occurred with secukinumab (incidence rate 19Á1 per 100 person-years). Four cases of cardiovascular events were reported during treatment with Data are mean AE SD or n (%). PASI, Psoriasis Area and Severity Index. a A patient can be treated multiple times with the same drug. Only the first series in which the patient is exposed to the drug is shown.
secukinumab (2% of treatment series), yielding a higher incidence rate (3Á1 per 100 person-years) than the other biologics (0Á1-0Á5 per 100 person-years). Recently, concern was raised regarding the relationship between IL-17 inhibition and inflammatory bowel disease (IBD). 22, 23 In DERMBIO, IBD is not coded as a separate adverse event. However, to assess the potential association, we searched the adverse event free-text field for any suspected or confirmed cases of new-onset, or exacerbation of, IBD (i.e. ulcerative colitis or Crohn disease) during biological therapy. A total of two cases were reported (0Á01% of all adverse events); one during treatment with adalimumab and one during treatment with infliximab, respectively. Incidence of adverse events was not higher for biosimilars than originators (Table S4 ; see Supporting Information). Kaplan-Meier plots of drug survival for the biological agents used to treat psoriasis. Drug survival rates for all treatment series showing discontinuation because of (a) any cause or because of (b) lack of efficacy. Drug survival rates for bio-na€ ıve patients showing discontinuation because of (c) any cause other than lack of efficacy or because of (d) lack of efficacy. Drug survival rates for patients previously exposed to biologics showing discontinuation because of (e) any cause other than lack of efficacy or because of (f) lack of efficacy.
Discussion
We provide long-term safety, efficacy, and drug survival data on anti-IL-12/23 and anti-TNF agents for moderate-to-severe psoriasis, and data on outcomes from more than 2 years of real-life treatment with secukinumab. To our knowledge, this is the first study to compare drug survival between originator and biosimilar versions of etanercept and infliximab among patients with psoriasis. As in previous studies, ustekinumab had higher drug survival than adalimumab, infliximab and etanercept. Forest plots of adjusted (sex, psoriatic arthritis, and concomitant methotrexate) hazard ratios for risk of (a) all-cause drug discontinuation in all treatment series; (b) all-cause drug discontinuation in bio-na€ ıve patients; (c) all-cause drug discontinuation in patients previously exposed to biologics; (d) discontinuation because of lack of efficacy of a second biologic following initial failure on one tumour-necrosis factor inhibitor because of lack of efficacy; (e) discontinuation because of lack of efficacy of a second biologic following initial failure on one interleukin-12/23 inhibitor because of lack of efficacy. Significant estimates with hazard ratios (HRs) greater than 1 favours the drug listed on the right, and vice versa [e.g. ustekinumab is favoured over infliximab in (a)]. CI, confidence interval.
Secukinumab was associated with the lowest drug survival of all investigated compounds. Although the observation time for secukinumab was only 2 years, a strikingly high proportion of secukinumab-treated patients discontinued their therapy during follow-up. This finding is consistent with a recent single-centre report of 90 patients treated with secukinumab, in which 30% of patients discontinued therapy before 32 weeks of treatment. 24 Consistent with clinical trial data, 2, 25 treatment with secukinumab yielded the highest proportion of PASI 100 respondents and displayed the most rapid onset of action. The same held true for absolute PASI reductions in bio-na€ ıve, but not non-na€ ıve patients. Previously, one systematic review found that in clinical trials, infliximab had the fastest onset of action, followed by ustekinumab, adalimumab, and etanercept, in that order. 26 For secukinumab, the low drug survival and the lower long-term efficacy compared with data from clinical trials is noticeable. The development of IL-17 inhibitors have been met with great anticipation, and PASI 90 has been suggested as the new gold standard for satisfactory treatment response. 27 Although speculative, clinicians' high expectations of the performance of secukinumab, especially in patients with concurrent PsA, could lead to an earlier switching to well-established PsA-approved therapies such as adalimumab if these predictions are not met. Moreover, the high proportion of patients returning to their previous therapy upon failing on secukinumab could suggest that these were controlled with an acceptable, but not complete, skin clearance and consequently switched to secukinumab in an attempt to obtain a lower absolute PASI score. Up-dosing, i.e. treatment with higher than approved dosages, was frequent for etanercept, infliximab and ustekinumab, which may reflect the physicians' attempts to maintain patients' response to treatment by increasing the dose or shortening the interval between administrations. Although ustekinumab showed the longest overall drug survival in this study, the frequent dose escalation (either higher dosages or shortening of the interval between injections) for this drug (which has flat pricing in Denmark) warrants attention.
No patients were treated with higher than approved dosages of secukinumab, which may reflect that use of this drug is relatively new to physicians. However, the markedly shorter drug survival of secukinumab is unlikely to be explained by lack of dose escalation. Indeed, less than 4% of adalimumab-treated patients received off-label dosing, and analysis of in-label dosing regimens showed higher drug survival for adalimumab (and ustekinumab) compared with secukinumab.
During our study, we identified no new safety signals for adalimumab, etanercept, infliximab and ustekinumab compared with previous reports. 6, 10, 28 However, contrasting previous findings, 21 infliximab had a lower incidence of infections, which may reflect that patients with a high risk of infections are not started on this therapy. Secukinumab had the highest rate of infections; furthermore, 2% of patients treated with this drug suffered a cardiovascular event yielding a conspicuously elevated incidence rate (Table S3 ) compared with findings from the secukinumab phase III clinical trial programme, 29 although the absolute numbers were very low (n = 4). No confirmed or suspected cases of IBD were reported during treatment with secukinumab.
Our study results support previous findings of higher drug survival of ustekinumab than anti-TNF agents. The high dropout rate for secukinumab (predominantly because of lack of efficacy) is noticeable, and future replication studies from other countries are warranted. As many non-na€ ıve patients were treated with secukinumab as their third or fourth biological therapy, these may comprise a group of patients who are particularly difficult to treat. Nevertheless, the low drug survival for secukinumab was seen even in bio-na€ ıve patients, and the cause may therefore in part be as a result of the antibody itself. However, only a limited number of secukinumabtreated patients were bio-na€ ıve (n = 42), and the results should thus be interpreted with caution. Although speculative, one potential explanation may be that antibodies may display differences in their binding affinity, for example for IL-17, and a stronger binding affinity is generally related to less disassociation from the antibody. Secukinumab, which is a medium affinity antibody, is given once a week for the first 4 weeks and thereafter once a month. The high loading dose can lead to a rapid and convincing response; however, over time the maintenance dose may be too low, leading to relapse at some threshold. Notably, although our long-term efficacy data for secukinumab contradict findings from randomized clinical trials, 30 the overall similar findings between the present study and previous drug survival studies published using the DERMBIO registry 6,13 support the robustness of our analyses.
In the case of anti-TNF agents, significant differences in drug survival rates were seen in this and in other studies. 6, 9, 10, 13 A number of potential explanations have been put forward, including differences in bioavailability, binding affinity of the drug and the presence or absence of antidrug antibodies. 10 As anti-IL-17 agents may differ in their binding affinity to IL-17, the degree of dissociation from these antibodies may vary. Consequently, it remains unclear whether the low secukinumab drug survival also holds true for other biologics targeting IL-17. We found no significant differences in drug survival for biosimilars compared with originators. Adverse events were also comparable with originators as seen in clinical trials and observational studies in rheumatology. 18, 31 In a recent study from the DANBIO registry 18 of rheumatology patients, Remsima was associated with a slightly (3Á4%) lower retention rate compared with Remicade (HR 1Á31 95% CI 1Á02-1Á68, P = 0Á03). Among a cohort of 30 Italian patients with psoriasis switching from Remicade to Remsima, no significant difference in PASI was observed over a median of 23 weeks (range 13-33 weeks) compared with the preswitch score. 32 We provide up to 2 years of data on biosimilars and secukinumab. However, we cannot refute that longer follow-up of treatment with these drugs may provide different results, as patient characteristics and prescription patterns could vary, and their efficacy might change with prolonged exposure. Switch from other compounds to a biosimilar (e.g. from adalimumab to biosimilar infliximab) because of price considerations is unlikely to have affected our results, as strict adherence to guidelines regarding the initiation and switching (including the order in which the drugs should be used) is enforced on a national level. These guidelines have been updated regularly, and may potentially bias interpretation, as this could have led to different prescription patterns during follow-up. Importantly, as previously argued, 19 biological registries are valuable tools to examine adverse events and monitor safety signals of rare outcomes, but between-drug comparisons should be cautioned. Indeed, patient characteristics, underlying considerations for choice of therapy and study results from a real-life setting may differ considerably from those of randomized clinical trials. 16, 19 In conclusion, among patients with moderate-to-severe plaque psoriasis, treatment with ustekinumab was associated with the highest drug survival, whereas the lowest was seen with secukinumab. However, interpretation was limited by the low number of treatment series with secukinumab (n = 196), of which only 42 patients were bio-na€ ıve. Consequently, definitive conclusions regarding this drug based on the present data should be cautioned. Switching from originator to biosimilar infliximab or etanercept had no significant impact on drug survival. Infections occurred more frequently with secukinumab, as did cardiovascular events (although the absolute number was low) and future studies are warranted to assess the long-term safety of novel biologics for psoriasis.
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